welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sulindac/Erlotinib Combo Tested in Patients with Familial Adenomatous Polyposis
A lower duodenal polyp burden was seen after 6 months of treatment with sulindac and erlotinib vs. placebo among patients with familial adenomatous polyposis (FAP), a study published in JAMA reports.
expertly curated content related to this topic
-
Current Status of Prophylactic Surgical Treatment for Familial Adenomatous Polyposis in JapanPURPOSE: We conducted this study to cla...
-
Nutritional Agents With Anti-inflammatory Properties in Chemoprevention of Colorectal NeoplasiaThe strong link between inflammation and...
-
Chemoprevention of Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) has...
-
Cancer Prevention Pharmaceuticals announces last patient completes phase 3 trial protocol of CPP-1X/sul for familial...Cancer Prevention Pharmaceutic...
-
Total Proctocolectomy, Ileal Pouch Anal Anastomosis (J-Pouch, S-Pouch, W-Pouch)http://my.clevelandclinic.org/ccf/media/...
-
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatou...Exisulind (sulindac sulfone; FGN-1), a m...
English
Portuguese
Spanish